Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
Makoto Yamakawa, Keiichi Nakahara, Toshihito Nakanishi, Toshiya Nomura, Mitsuharu Ueda
Abstract
After BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination, a 30-year-old man developed bilateral lateral gaze palsy, diplopia, absent tendon reflexes, and ataxic gait. Serum anti-GQ1b and anti-GT1a immunoglobulin G (IgG) antibodies were strongly positive. Based on those findings, he was diagnosed with Miller Fisher syndrome (MFS). Intravenous immunoglobulin therapy was administered, and his symptoms fully recovered within approximately 3 months. To the best of our knowledge, this is the first report to describe the development of MFS after COVID-19 mRNA vaccination.
Topics & Concepts
MedicineMiller-Fisher syndromeVaccinationDiplopiaAntibodyCoronavirus disease 2019 (COVID-19)ImmunologyPediatricsInternal medicineDiseaseSurgeryInfectious disease (medical specialty)Peripheral Neuropathies and DisordersSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19